NIAID holds closed meeting to discuss radiation injury grants
The NIAID Special Emphasis Panel has scheduled the Development of Medical Countermeasures for Post-Exposure Mitigation/Treatment of Injuries Resulting from a Radiation/Nuclear Incident for March 6-7 in Silver Spring, Maryland. The agenda is to review and evaluate grant applications.
The meeting will be closed to the public in accordance with regulations concerning the possible disclosure of confidential trade secrets or commercial property such as patentable material and personal information. Disclosing this information in a public setting is considered to constitute a clearly unwarranted invasion of personal privacy.
The institute currently runs the Medical Countermeasures against Radiological and Nuclear Threats. NIAID is responsible for guiding all activities of the U.S. National Institutes of Health concerning radiation and nuclear MCMs. It also runs a similar program with regards to chemical MCMs. The bulk of NIAID's biodefense research focuses on therapies for potentially dangerous pathogens.
NIAID, which operates under the NIH and the U.S. Department of Health and Human Services, conducts and supports research into infectious, immunologic and allergic diseases. It has been operating for over 60 years.